Hepatitis C Virus Glycoproteins Mediate PH-dependent Cell Entry of Pseudotyped Retroviral Particles

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 May 23

PMID 12761383

Citations 380

Authors

Mayla Hsu

Jie Zhang

Mike Flint

Carine Logvinoff

Cecilia Cheng-Mayer

Charles M Rice

Jane A McKeating

Affiliations

Soon will be listed here.

Abstract

HIV pseudotypes bearing native hepatitis C virus (HCV) glycoproteins (strain H and Con1) are infectious for the human hepatoma cell lines Huh-7 and PLC/PR5. Infectivity depends on coexpression of both E1 and E2 glycoproteins, is pH-dependent, and can be neutralized by mAbs mapping to amino acids 412-447 within E2. Cell-surface expression of one or all of the candidate receptor molecules (CD81, low-density lipoprotein receptor, scavenger receptor class B type 1, and dendritic cell-specific intercellular adhesion molecule 3 grabbing nonintegrin) failed to confer permissivity to HIV-HCV pseudotype infection. However, HIV-HCV pseudotype infectivity was inhibited by a recombinant soluble form of CD81 and a mAb specific for CD81, suggesting that CD81 may be a component of a receptor complex.

Citing Articles

Tetraspanin CD81 serves as a functional entry factor for porcine circovirus type 2 infection.

Li J, Lv L, Gao Y, Sun Y, Bai J, Wang X J Virol. 2025; 99(2):e0140824.

PMID: 39745447 PMC: 11853000. DOI: 10.1128/jvi.01408-24.

Poly(rC)-Binding Protein 2 Does Not Directly Participate in HCV Translation or Replication, but Rather Modulates Genome Packaging.

Cousineau S, Camargo C, Sagan S Viruses. 2024; 16(8).

PMID: 39205194 PMC: 11359930. DOI: 10.3390/v16081220.

Pseudovirus-Based Systems for Screening Natural Antiviral Agents: A Comprehensive Review.

Trischitta P, Tamburello M, Venuti A, Pennisi R Int J Mol Sci. 2024; 25(10).

PMID: 38791226 PMC: 11121416. DOI: 10.3390/ijms25105188.

Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection.

Frumento N, Sinnis-Bourozikas A, Paul H, Stavrakis G, Zahid M, Wang S Immunity. 2024; 57(1):40-51.e5.

PMID: 38171362 PMC: 10874496. DOI: 10.1016/j.immuni.2023.12.004.

ASPP2 binds to hepatitis C virus NS5A protein via an SH3 domain/PxxP motif-mediated interaction and potentiates infection.

Smirnov A, Magri A, Lotz R, Han X, Yin C, Harris M J Gen Virol. 2023; 104(9).

PMID: 37750869 PMC: 7615710. DOI: 10.1099/jgv.0.001895.

References

Higginbottom A, Quinn E, Kuo C, Flint M, WILSON L, Bianchi E . Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol. 2000; 74(8):3642-9. PMC: 111874. DOI: 10.1128/jvi.74.8.3642-3649.2000. View

Tan R, Harouse J, Gettie A, Cheng-Mayer C . In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein. J Med Primatol. 1999; 28(4-5):164-8. DOI: 10.1111/j.1600-0684.1999.tb00265.x. View

Agnello V, Abel G, Elfahal M, Knight G, Zhang Q . Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1999; 96(22):12766-71. PMC: 23090. DOI: 10.1073/pnas.96.22.12766. View

Wellnitz S, Klumpp B, Barth H, Ito S, Depla E, Dubuisson J . Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol. 2002; 76(3):1181-93. PMC: 135804. DOI: 10.1128/jvi.76.3.1181-1193.2002. View

Lozach P, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A . DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem. 2003; 278(22):20358-66. DOI: 10.1074/jbc.M301284200. View

Matsuura Y, Tani H, Suzuki K, Suzuki R, Aizaki H, Ishii K . Characterization of pseudotype VSV possessing HCV envelope proteins. Virology. 2001; 286(2):263-75. DOI: 10.1006/viro.2001.0971. View

Clayton R, Owsianka A, Aitken J, Graham S, Bhella D, Patel A . Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol. 2002; 76(15):7672-82. PMC: 136371. DOI: 10.1128/jvi.76.15.7672-7682.2002. View

Skehel J, Wiley D . Coiled coils in both intracellular vesicle and viral membrane fusion. Cell. 1999; 95(7):871-4. DOI: 10.1016/s0092-8674(00)81710-9. View

Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A . Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996; 93(26):15394-9. PMC: 26415. DOI: 10.1073/pnas.93.26.15394. View

10.

Dubuisson J . Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol. 1999; 242:135-48. DOI: 10.1007/978-3-642-59605-6_7. View

11.

Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud M, Trepo C . In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998; 91(10):3841-9. View

12.

Buonocore L, Blight K, Rice C, Rose J . Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol. 2002; 76(14):6865-72. PMC: 136334. DOI: 10.1128/jvi.76.14.6865-6872.2002. View

13.

Bartosch B, Dubuisson J, Cosset F . Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003; 197(5):633-42. PMC: 2193821. DOI: 10.1084/jem.20021756. View

14.

Wunschmann S, Medh J, Klinzmann D, Schmidt W, Stapleton J . Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol. 2000; 74(21):10055-62. PMC: 102044. DOI: 10.1128/jvi.74.21.10055-10062.2000. View

15.

Roberts P, Kipperman T, Compans R . Vesicular stomatitis virus G protein acquires pH-independent fusion activity during transport in a polarized endometrial cell line. J Virol. 1999; 73(12):10447-57. PMC: 113100. DOI: 10.1128/JVI.73.12.10447-10457.1999. View

16.

Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R . Binding of hepatitis C virus to CD81. Science. 1998; 282(5390):938-41. DOI: 10.1126/science.282.5390.938. View

17.

Sung V, Shimodaira S, Doughty A, Picchio G, Can H, Yen T . Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol. 2003; 77(3):2134-46. PMC: 140883. DOI: 10.1128/jvi.77.3.2134-2146.2003. View

18.

Lagging L, Meyer K, Owens R, Ray R . Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol. 1998; 72(5):3539-46. PMC: 109573. DOI: 10.1128/JVI.72.5.3539-3546.1998. View

19.

Quinn E, Chan C, Hadlock K, Foung S, Flint M, Levy S . The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001; 98(13):3745-9. DOI: 10.1182/blood.v98.13.3745. View

20.

Flint M, Thomas J, Maidens C, Shotton C, Levy S, Barclay W . Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol. 1999; 73(8):6782-90. PMC: 112763. DOI: 10.1128/JVI.73.8.6782-6790.1999. View